Recurrent SARS-CoV-2 Infection and Impaired Immunologic Response in a Pediatric Oncologic Patient While Treated With Radiochemotherapy

Pediatr Infect Dis J. 2022 Jun 1;41(6):e259-e262. doi: 10.1097/INF.0000000000003515. Epub 2022 May 6.

Abstract

Immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pediatric patients with malignant disease may be affected by tumor therapy. Here, we report the case of a child with rhabdomyosarcoma and recurrent SARS-CoV-2 infection. Immunologic responses, analyzed by T-cell activity and anti-viral IgG levels, were impaired and not durable as a result of intensive radiochemotherapy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19*
  • Chemoradiotherapy
  • Child
  • Humans
  • SARS-CoV-2
  • T-Lymphocytes

Substances

  • Antibodies, Viral